06:48:22 Europe / Stockholm
Svenska | English

BBS-Bioactive Bone Substitutes

Attachments

Share price & Turnover

Share price change and turnover during the day of this press release

Subscription

Calendar

2025-02-21 Year-end Report 2024
2024-08-09 Half year report
2024-06-13 Annual General meeting
2024-05-02 Ex-date Ordinary Dividend BONEH 0.00 EUR
2024-02-26 Year-end Report 2023
2023-10-23 Extra General Meeting 2023
2023-08-25 Half year report
2023-05-02 Ex-date Ordinary Dividend BONEH 0.00 EUR
2023-04-28 Annual General meeting
2023-02-24 Year-end Report 2022
2022-08-25 Half year report
2022-04-29 Ex-date Ordinary Dividend BONEH 0.00 EUR
2022-04-28 Annual General meeting
2022-03-17 Extra General Meeting 2022
2022-02-24 Year-end Report 2021
2021-08-25 Half year report
2021-04-29 Ex-date Ordinary Dividend BONEH 0.00 EUR
2021-04-28 Annual General meeting
2021-02-24 Year-end Report 2020
2020-08-31 Half year report
2020-04-06 Ex-date Ordinary Dividend BONEH 0.00 EUR
2020-04-05 Annual General meeting
2020-03-20 Year-end Report 2019
2019-08-30 Half year report
2019-04-08 Ex-date Ordinary Dividend BONEH 0.00 EUR
2019-04-05 Annual General meeting
2018-08-30 Half year report
2018-03-29 Annual General meeting

Description

CountryFinland
ListFirst North Finland
SectorHealth care
IndustryMedical technology
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd
2024-05-21 16:00:00

BBS-Bioactive Bone Substitutes Plc | Company Release | May 21, 2024 at 17:00:00 EEST

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

BBS-Bioactive Bone Substitutes Plc ("BBS") has received 21 May 2024 requests from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert a proportion of EUR 50,000 of the convertible notes into Company shares at a conversion price of EUR 0.32247 per share. The conversion shall be executed by transferring a total of 155,053 treasury shares to Riverfort.

The Conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.

After the transfers, the Company will hold a total of 216,647 treasury shares in its possession.

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

Source MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

An email has been sent to the given address. To login please click "Login" in that email to verify your account

Companies

Press releases